Hillgene Lentiviral Vector CDMO Features

 Hillgene offers end-to-end lentivirus CDMO services for lentiviral vector production, providing high-quality, scalable, and regulatory-compliant solutions for cell and gene therapy developers, from initial plasmid design and vector construction to GMP-grade manufacturing and rigorous quality control testing. With extensive experience in lentivirus production and a strong focus on viral safety and consistency, Hillgene ensures rapid timelines and flexible batch sizes. We specialize in both research-grade and clinical-grade lentiviral vectors tailored to client needs. Our state-of-the-art facilities are equipped to support CAR-T, CAR-NK, and other cell therapy applications. As a trusted lentiviral vector CDMO partner, Hillgene follows strict GMP guidelines and global regulatory standards. Partner with Hillgene to accelerate your gene therapy pipeline with reliable, scalable, and cost-effective lentiviral vector manufacturing services.

 

Hillgene can provide the following lentiviral vector car t cdmo services at different stages

 

Hillgene can provide the following CDMO services at different stages

 

Lentiviral Vector CDMO System

Self-adapted third-generation quad plasmid vector system

 

With traditional VSVG and novel envelope

 

Completed DMF filing

 

Lentiviral Vector Suspension System

Virus Expressed 293T serum-free culture technology

 

Disposable bioreactors

 

Yield: Up to 2E11TU/50L

 

Scale: From Scale: From 10L up to 100L

 

Data on T cells translated by different LVV

 

Transduction Effect

Different GOI lengths, at a lower MOI, can obtain a high positive rate, low copy number of the cell products

 

Can be applied to different cells

 

CAR-T therapy for Solid tumors

 

TCR-T cell therapeutics

 

Gene-edited HSCs

 

UCAR-T cell therapeutics

 

CAR-NK cell therapeutics

 

iPS-CAR -NK cell therapeutics

 

Hillgene Lentivirus CDMO Case Studies

Case 1: Dual-Target CAR-T Therapy

Background

 

A biotech startup developing dual-target CAR-T therapy for hematological cancers required cGMP-grade lentiviral vector production at 10L scale. The vector needed to carry a 2950bp insert with target specifications of >1E8 TU/mL titer, >50% positivity rate, and VCN<5 copies/cell to support 500 patient doses.  

 

Key Challenge

 

Large insert size significantly reduced viral packaging efficiency. Maintaining high titer while achieving high transduction efficiency in T-cells proved difficult. The tight 8-month timeline for process development and GMP production added complexity.  

 

Optimization

 

Implemented high-density culture with optimized transfection reagents  

 

Developed a dual-promoter system to enhance transgene expression  

 

Established a three-step chromatography purification process  

 

Introduced a real-time VCN monitoring and control system  

 

Result

 

Achieved 1.4E8 TU/mL titer with 53.7% positivity rate  

 

Maintained VCN at 4.1 copies/cell  

 

Completed 3 cGMP batches within 8 months  

 

Single batch yielded 1.6E10 TU, sufficient for 530 patient doses

 

Case 2: CAR-NK Cell Therapy

 

Background

 

A research spin-off needed large-scale lentiviral vector production at 20L scale for off-the-shelf CAR-NK therapy. Requirements included >1E7 TU/mL titer, >40% positivity rate, and VCN<5 copies/cell to support 10 cell production batches.  

 

Key Challenge

 

Low NK cell transduction efficiency required an exceptionally high viral titer. Scaling to 20L while maintaining consistency and meeting the 5-month timeline for the engineering run was critical.  

 

Optimization

 

Optimized serum-free suspension culture conditions  

 

Developed specialized transduction enhancers for NK cells  

 

Implemented automated monitoring and control systems  

 

Established rapid quality release protocols  

 

Achieved 3.8E7 TU/mL titer with 43.6% positivity rate  

 

Maintained VCN below 5 copies/cell  

 

Completed engineering run within 5 months  

 

Single batch supported 15 cell production runs  

 

Case 3: TCR-T Cell Therapy

 

Background

 

A clinical-stage company required GMP lentiviral vector production for TCR-T therapy at a 10L scale. Specifications included >5E8 TU/mL titer, >30% positivity rate for 1950bp insert, and VCN<5 copies/cell to treat 80 patients.  

 

Key Challenge

 

Ultra-high titer requirement combined with the need for precise TCR expression. Tight 7-month timeline for GMP production and stringent regulatory compliance requirements.  

 

Optimization

 

Developed high-titer packaging cell line  

 

Implemented ultra-filtration concentration technology  

 

Established a comprehensive quality control system  

 

Optimized vector construct for accurate TCR expression  

 

 

Achieved 6.8E8 TU/mL titer with 36.4% positivity rate  

 

Maintained VCN at 4.5 copies/cell  

 

Completed GMP production within 7 months  

 

Single batch yielded 9.8E10 TU, sufficient for 98 patients  

 

Case 4: HSC Gene Therapy

 

Background

 

A university-hospital partnership needed large-scale lentiviral vector production at 100L scale for HSC gene therapy. The 4433bp insert required >2E8 TU/mL titer and VCN >3 copies/cell to treat 250 patients.  

 

Key Challenge

 

Extremely large insert size near packaging limit. Massive 100L scale production while maintaining quality. The requirement for high VCN in HSCs added complexity.  

 

Optimization

 

Developed novel capsid proteins for improved packaging  

 

Implemented parallel bioreactor operation strategy  

 

Optimized transduction protocol for HSCs  

 

Established a comprehensive safety testing regimen  

 

Result

 

Achieved 3.2E8 TU/mL titer despite large insert size  

 

Maintained VCN at 3.6 copies/cell in HSCs  

 

Completed 100L GMP production within 8 months  

 

Single batch yielded 2.8E11 TU, sufficient for 300 patients

 

For more information about cell therapy cdmo services, please feel free to contact us!